Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie A D Haverkort

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 14, 2012
Adaptive margin radiotherapy for patients with prostate carcinoma: what's the benefit?Marie A D Haverkort, Jeroen B van de Kamer, Bradley R Pieters, et al.
Brachytherapy|May 23, 2017
In vivo dosimetry in gynecological applications-A feasibility studyMarion P R Van Gellekom, Richard A M Canters, Frank J W M Dankers, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2010
Position verification for the prostate: effect on rectal wall doseMarie A D Haverkort, Jeroen B van de Kamer, Bradley R Pieters, et al.
Brachytherapy|January 7, 2026
Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patientsMax Peters, Tonnis T Nuver, Marnix J A Rasing, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2024
Retinoblastoma Protein Loss in p53 Abnormal Endometrial Carcinoma: Histologic and Clinicopathological CorrelatesEzgi Dicle Serbes, Nanda Horeweg, Carlos Parra-Herran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial CancerNanda Horeweg, Remi A Nout, Ina M Jürgenliemk-Schulz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 8, 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter HypermethylationMerve Kaya, Cathalijne C B Post, Carli M Tops, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial CarcinomasAmy Jamieson, Lisa Vermij, Claire J H Kramer, et al.
Gynecologic Oncology|March 13, 2021
Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision makingCathalijne C B Post, Jan Willem M Mens, Marie A D Haverkort, et al.
JCO Global Oncology|May 25, 2023
<i>QPOLE</i>: A Quick, Simple, and Cheap Alternative for <i>POLE</i> Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain ReactionAnne Sophie V M Van den Heerik, Natalja T Ter Haar, Lisa Vermij, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 14, 2012
Adaptive margin radiotherapy for patients with prostate carcinoma: what's the benefit?Marie A D Haverkort, Jeroen B van de Kamer, Bradley R Pieters, et al.
Brachytherapy|May 23, 2017
In vivo dosimetry in gynecological applications-A feasibility studyMarion P R Van Gellekom, Richard A M Canters, Frank J W M Dankers, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2010
Position verification for the prostate: effect on rectal wall doseMarie A D Haverkort, Jeroen B van de Kamer, Bradley R Pieters, et al.
Brachytherapy|January 7, 2026
Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patientsMax Peters, Tonnis T Nuver, Marnix J A Rasing, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2024
Retinoblastoma Protein Loss in p53 Abnormal Endometrial Carcinoma: Histologic and Clinicopathological CorrelatesEzgi Dicle Serbes, Nanda Horeweg, Carlos Parra-Herran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial CancerNanda Horeweg, Remi A Nout, Ina M Jürgenliemk-Schulz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 8, 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter HypermethylationMerve Kaya, Cathalijne C B Post, Carli M Tops, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial CarcinomasAmy Jamieson, Lisa Vermij, Claire J H Kramer, et al.
Gynecologic Oncology|March 13, 2021
Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision makingCathalijne C B Post, Jan Willem M Mens, Marie A D Haverkort, et al.
JCO Global Oncology|May 25, 2023
<i>QPOLE</i>: A Quick, Simple, and Cheap Alternative for <i>POLE</i> Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain ReactionAnne Sophie V M Van den Heerik, Natalja T Ter Haar, Lisa Vermij, et al.
Pageof 2